KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to $188000.0.

  • Pacific Biosciences Of California's Change in Accured Expenses rose 10550.51% to $188000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year increase of 8785.94%. This contributed to the annual value of -$26.3 million for FY2024, which is 30103.79% down from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Change in Accured Expenses of $188000.0 as of Q3 2025, which was up 10550.51% from -$4.8 million recorded in Q2 2025.
  • Pacific Biosciences Of California's 5-year Change in Accured Expenses high stood at $11.0 million for Q4 2023, and its period low was -$23.8 million during Q1 2024.
  • In the last 5 years, Pacific Biosciences Of California's Change in Accured Expenses had a median value of $503000.0 in 2024 and averaged -$199421.1.
  • As far as peak fluctuations go, Pacific Biosciences Of California's Change in Accured Expenses soared by 254389.44% in 2023, and later crashed by 104493.04% in 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Change in Accured Expenses (Quarter) stood at $5.1 million in 2021, then soared by 46.51% to $7.4 million in 2022, then soared by 49.24% to $11.0 million in 2023, then crashed by 97.08% to $323000.0 in 2024, then tumbled by 41.8% to $188000.0 in 2025.
  • Its Change in Accured Expenses stands at $188000.0 for Q3 2025, versus -$4.8 million for Q2 2025 and $2.3 million for Q1 2025.